GEN: CEO Dave Johnson discusses GigaGen technology in Antibody Screening is Never Out of Sorts

,

“The idea behind our approach is that we can run a sample of cells through a microfluidic device that we designed and go very deep into the antibody repertoires,” says David S. Johnson, PhD, CEO and co-founder of GigaGen. The approach developed by GigaGen combines the use of emulsion droplet microfluidics with yeast single-chain variable fragment (scFv) display and molecular genomics. “The challenge,” Johnson explains, “is keeping the heavy and light chains of the antibodies intact at a single-cell level to maintain the functionality of the antibodies.”

Read the full article.

Scrip: CEO Dave Johnson Discusses Commercializing Advanced Therapies in Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business and Investment

,

With drug price sensitivity persisting, David Johnson, CEO of GigaGen, believes “an important focus for early-stage drug developers will be to innovate in approaches that
simultaneously improve patient care and reduce costs to the health system. Drugs that are safer than existing drugs could be priced competitively with incumbents but reduce costs to the health system by requiring less inpatient care. Drugs that are more potent per gram could be priced competitively with lower-potency incumbents, increasing profits for the manufacturer and decreasing infusion times for the patient. Processes that are difficult to scale, such as cell therapy manufacturing, will become increasingly streamlined, allowing manufacturers to reduce prices while increasing profits.”

Read the full story.

BioSpace: GigaGen’s Recombinant IVIG Technology Could Be Potential Solution to Global Shortage

,

A critical supply shortage of intravenous immunoglobulin (IVIG) in the United States has left some room for doubt about whether or not that critical care will make it to some patients.

IVIG contains antibodies that are harvested from plasma provided by thousands of donors across the country. IVIG, which is injected into patients, helps them fight off various infections. IVIG is also used to treat some disorders of the muscles and nervous system. A shortage, which the U.S. Food and Drug Administration confirmed in August, increases the risk to patients. In its announcement, the FDA said some hospitals, medical systems and other health care providers have taken steps to “optimize” limited supplies of IVIG products. Some of those optimization strategies include the lowering of doses, delay of treatments, alternative therapies where applicable and prioritization based on medical need.

In a report on the state of the IVIG supply, The Wall Street Journal noted that IVIG suppliers like Octopharma, which develops products for Pfizer, and Takeda are boosting production of their products in order to meet demand. However, those companies noted that some delays in manufacturing and shipping are likely to continue to impact the supply levels.

While the nation grapples with the shortage, California-based GigaGen may have a solution to prevent future shortages – but it’s a solution that is still a few years off. GigaGen is developing a new approach to current IVIG therapies that is not subject to supply shortages and overcomes other significant challenges of plasma-based products. The company uses a proprietary platform to create recombinant polyclonal immunoglobulin (IgG) therapies that don’t rely on human plasma supplies.

Read the full story.

Biocom: CSO Adam Adler named a Biocom Catalyst Award Winner

,

Biocom, the association representing the California life science industry, today announced the winners of its Fourth Annual Catalyst Awards. The awards identify accomplished and up-and-coming academics, entrepreneurs, investors, corporate leaders and business advisers who are making their mark on the San Diego, Los Angeles and Bay Area life science industries before reaching their 40th birthday.

Read the full press release.

 

PharmaVOICE: CEO Dave Johnson named one of the 100 Most Inspiring People

,

Big Picture, Big Rewards – David Johnson, Ph.D., locks up his bicycle after a harrowing ride navigating hills and traffic to make his way to South San Francisco, Calif., the birthplace of biotechnology. It’s how he gets to and from work at GigaGen, a company he founded in 2010 to translate his research in single cell genomics into novel therapies for patients in need.

Read the full story.

GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of cells in search of promising drug targets and therapeutic candidates.

Read the full press release.

BioSpace: 6 Award-Winning Life Science Companies in the Bay Area

,

There are numerous ways to rank a company as “the best place to work.” Some listings rank companies by pay, others by how “happy and engaged” the workforce is, others by culture and benefits. Some rankings use metrics while others are based on employee surveys. Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.

GigaGen. Based in South San Francisco, GigaGen is a small biotech company working to advance a pipeline of immunotherapies for cancer and immune deficiencies. The company’s tech platform, dubbed Surge technology, leverages microfluidics, genomics and protein library engineering to improve target selection, candidate identification and preclinical efficacy assessment. The company recently published an article in the journal mAbs showing the feasibility and benefit of its Surge antibody discovery and engineering platform for rapid monoclonal antibody discovery. GigaGen was recently ranked as one of the “Best Places to Work in the Bay Area” by the San Francisco Business Journal.

Read the full story.

GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study that shows the feasibility and benefit of its Surge™ antibody discovery and engineering platform for rapid monoclonal antibody discovery using multiple immunization protocols in parallel. The study has been published online in the peer-reviewed scientific journal mAbs, and it will be available as the cover article in the upcoming July printed issue.

Read the full press release.

STAT: GigaGen CEO Dave Johnson, PhD, discusses why biotech execs need to create an environment that fosters a truly scientific culture

,

“What traditions do you want to follow for your baby?” asked the midwife leading our prenatal education group.

As we went around the circle of parents-to-be, most couples discussed holiday traditions, camping trips, and weekend routines. When it was my turn to share, I thought about the pseudoscience that had been espoused in this group — the alleged benefits of eating the placenta, theories about the harmful effects of vaccines, and the like.

“I want a facts-based, scientific household,” I said. “For example, is breastfeeding better than formula? To me the only thing that matters is the clear scientific consensus that breastfed infants grow up to be, on average, advantaged in some way — maybe healthier or smarter.”

Read the full story.

GigaGen CEO David Johnson to Present on Surge Technology at 2019 Antibody Engineering & Therapeutics Asia Meeting

,

GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting. Dr. Johnson will also co-chair the presentation, which will take place at 8:45 a.m. JST on February 26, 2019, at the Hilton Tokyo Bay Hotel in Tokyo, Japan.

Read the full press release.